|| Glibenclamide IP
|| Aventis Pharma Ltd.
What is Daonil?
Daonil (Glibenclamide) is prescribed for type 2 diabetes (non-insulin dependent diabetes) in adults, when diet therapy proves to be inefficient.
How is Daonil used?
The dosage is prescribed individually, depending on age, severity of diabetes, levels of glycemia, including fasting test and in two hours after a meal.
The average dosage amounts to 2.5-15mg per day, administered 1-3 days per day. It is taken 20-30 minutes before meals. Doses exceeding 15mg per day are used rarely and do not lead to any significant increase in their hypoglycemic effect.
For elderly patients the initial dose is 1mg per day.
When transitioning from Biguanides to Glibenclamide, the initial dose of Glibenclamide should be 2.5mg per day.
Biguanides should be cancelled, while the dose of Glibenclamide can be increased by 2.5mg every 5-6 days until carbohydrate metabolism disorders are compensated. In case the compensation is not achieved within 4-6 weeks, it is essential to plan a combination therapy with Glibenclamide and Biguanides.
Endocrine system: hypoglycaemia up to coma (the risks of a coma are higher in case of dosing schedule violations and inadequate diet).
Allergic reactions: skin rash, skin itching.
Digestive system: nausea, diarrhea, sensation of heaviness in the upper abdomen; rare - liver function disorders, cholestasis.
Central and peripheral nervous system: rare - paresis, sensation disorders, headache, tiredness, weakness, dizziness.
Hemopoietic system: rare - blood formation disorders up to pancytopenia.
Dermatological reactions: rare - photosensitization.
Daonil (Glibenclamide) should be used with caution in patients with liver and kidney diseases (including past medical history), as well as fever, adrenal glands function disorders, thyroid function disorders, and chronic alcohol addiction.
During the therapy with Daonil (Glibenclamide), it is essential to monitor blood glucose and urinary glucose excretion on a regular basis.
In case of hypoglycaemia, if a patient is conscious, glucose (or sugar solution) is administered by mouth. If a patient is unconscious, glucose is administered intravenously or glucagon is administered subcutaneously, intramuscularly, or intravenously. After the patient recovers, it is essential to give the patient a carbohydrate-rich meal to avoid repeated hypoglycaemia.
Patients taking Daonil (Glibenclamide) should avoid alcohol consumption. Alcohol consumption may lead to disulfiram-like reactions, as well as severe hypoglycaemia.
Daonil (Glibenclamide) counter indications:
- Type 1 diabetes (insulin-dependent diabetes), ketoacidosis, diabetic precoma and coma, severe microcirculatory disorders, infectious diseases, severe kidney and/or liver function disorders.
- Hypersensitivity to sulfonylureas and sulfanilamides.
Daonil (Glibenclamide) is not used during serious surgeries.